SMMT

Summit Therapeutics Inc. SMMT

NasdaqLarge CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-215.70M

Quarter to Jun 30

Free cash flow

$-142.03M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$1.98B total
BAKER BROS. ADVISORS LP
$477.70M-9.9%
FMR LLC
$146.34M-7.5%
STATE STREET CORP
$138.95M+35.7%
BlackRock, Inc.
$138.84M-1.3%
VANGUARD CAPITAL MANAGEMENT LLC
$83.55M+0.4%
UBS Group AG
$76.26M+42.2%
VANGUARD PORTFOLIO MANAGEMENT LLC
$73.46M-3.7%
GOLDMAN SACHS GROUP INC
$65.76M+1352.5%
PRICE T ROWE ASSOCIATES INC /MD/
$56.73M-53.0%
Point72 Asset Management, L.P.
$53.88M+371.5%
GEODE CAPITAL MANAGEMENT, LLC
$49.95M+3.4%
MILLENNIUM MANAGEMENT LLC
$34.23M+1760.3%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$28.99MNew
BALYASNY ASSET MANAGEMENT L.P.
$27.74M+247.3%
CITADEL ADVISORS LLC
$25.14M+290.7%
abrdn plc
$24.68M+154.5%
Squarepoint Ops LLC
$23.18M+159.1%
MORGAN STANLEY
$21.13M-12.2%
NORGES BANK
$20.14M--
Logos Global Management LP
$19.67MNew
Octagon Capital Advisors LP
$18.21MNew
D. E. Shaw & Co., Inc.
$18.12M-44.5%
Kynam Capital Management, LP
$17.48MNew
Pictet Asset Management Holding SA
$16.43M-14.3%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$14.23M+1.7%
See all 246 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SMMT

Earnings Per Share

13fpro.ai/company/SMMT

Loading ratio trend…

SMMT key financials by period

Reported revenue, net income and operating margin by fiscal year, from Summit Therapeutics Inc.'s annual filings on SEC EDGAR.

Summit Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2022$705.0K$-78.8M—
FY 2021$1.8M$-88.6M—
FY 2020$860.0K$-52.7M—
FY 2019$743.0K$-29.1M—
FY 2019$57.1M$10.9M9.4%
FY 2018$16.1M$-26.4M-176.2%
Source: SMMT filings on SEC EDGAR →

SMMT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Summit Therapeutics Inc. (SMMT): stock profile, AI score and financials

Summit Therapeutics Inc. (SMMT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SMMT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Summit Therapeutics Inc. reports net income of $-215.7M, free cash flow of $-142.0M. Top institutional holders of SMMT by reported 13-F value include BAKER BROS. ADVISORS, FMR, STATE STREET, based on the most recent SEC filings. SMMT trades on the Nasdaq exchange and files with the SEC under CIK 1599298. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SMMT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Summit Therapeutics Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1599298 →